K. Vera

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.

E. Raymond, J. Armand, S. Faivre, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

E. Raymond, S. Faivre, A. Gianella-Borradori, 2010, European journal of cancer.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

E. Raymond, C. Robert, J. Armand, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

E. Raymond, S. Faivre, M. Marty, 2008, Investigational New Drugs.

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.

M. Rizzo, G. Recondo, R. Kowalyszyn, 2020, Clinical lung cancer.

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

E. Raymond, S. Faivre, M. Marty, 2008, Investigational new drugs.

Analysis of Survival in 400 Surgically Resected Non-small Cell Lung Carcinomas: Towards a Redefinition of the T Factor

G. Lyons, D. Chimondeguy, S. Quadrelli, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study

H. Gómez, R. Cristescu, T. Ciuleanu, 2021, Clinical Trials.